News & events

Press releases

17 January 2022, Sophia-Antipolis, France

Median Technologies Announces 2021 Revenue of €20.5 Million, Up 52%, and a Strengthened Cash Position of €39 Million

As of December 31, 2021, Median Technologies’ revenue was €20.5 million, a 52% increase compared to 2020 revenue. The order backlog as of December 31, 2021, was €58 million, a €6.3 million increase compared to December 31, 2020 and a €3,8 million increase compared to September 30, 2021. As of December 31, 2021, cash and cash equivalents were €39 million, compared to €16 million as of December 31, 2020.

Read more
See all press releases


November 28 - December 2, 2021 | McCormick Place, Chicago, IL, USA

RSNA 2021

Median will be exhibiting at the RSNA 2021 Annual Meeting, which will take place from November 28 to December 2 in Chicago. We will be so pleased to see you in person at our booth #4849 South Hall A Level 3, to talk about the latest advancements of our iBiopsy® AI-powered Software as a Medical Device (SaMD). Happy to see you there during the whole exhibition duration, from November 28 to December 1.

Visit conference website
See all conferences

In the press

iBiopsy® for Precision Medicine

Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® ->


A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press


See all blog entries


February 1, 2022

Discuss the 4 main causes of variability in centralized oncology radiological assessments

Inter-reader variability can create challenges in oncology trial results. During this 45-minute webinar, Median Technologies will address the 4 main causes of variability occurring during RECIST1.1 assessment and describe control strategies using data analytics and medical investigations. During this presentation, you will:

  • Discover the most common types of reader discrepancies in oncology follow-up
  • Learn how to control the causes of variability in centralized independent review and how to prevent them
  • Grasp how we at Median Technologies, handle inter-reader variability through our methods and strategies


  • Antoine Iannessi, Medical Director, Median Technologies
  • Emilie Serres, Clinical Research Scientist, Median Technologies
Register here
See all webinars